AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2015

November 2015, Boston, Massachusetts
Abstract: RRx-001 combined with anti-PD-L1 antibody increases the complete response rate in a preclinical myeloma model